The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.
June 16th 2024
Treatment with FDA-approved CAR T-cell therapies for non-Hodgkin lymphoma was efficacious and feasible in patients with Richter transformation.
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients With CRPC
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fixed-Duration Glofitamab Elicits Early, Durable Complete Remissions in Relapsed/Refractory LBCL
Michael Dickinson, MBBS, expands on data from a phase 2 dose-expansion study of glofitamab in heavily pretreated, highly refractory large B-cell lymphoma, explains the effect bispecific antibodies could have on treatment, and highlights other research efforts surrounding glofitamab-based therapies.
Approval Sought for Tafasitamab/Lenalidomide Combo in R/R DLBCL in Hong Kong
The Hong Kong Special Administrative Region’s Department of Health has accepted for review a biologics license application seeking the approval of tafasitamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Relma-cel Demonstrates Durable Activity in Relapsed/Refractory LBCL
Relmacabtagene autoleucel elicited durable responses and a high overall survival rate in Chinese patients with relapsed/refractory large B-cell lymphoma, according to 2-year follow-up data from the phase 2 RELIANCE trial.
The combination of lenalidomide and rituximab demonstrated durable safety and efficacy that was comparable to that achieved with rituximab plus chemotherapy in previously untreated patients with follicular lymphoma, according to 6-year data from the phase 3 RELEVANCE trial.
FDA Accepts sBLA for Polatuzumab Vedotin Plus R-CHP in Untreated DLBCL
The FDA has accepted a supplemental biologics license application for the combination of polatuzumab vedotin and R-CHP as a treatment for patients with previously untreated diffuse large B-cell lymphoma.
Raul Cordoba, MD, PhD, discussed the efficacy and safety findings from cohort 4 of the EPCORE NHL-2 trial, the benefits observed with epcoritamab monotherapy in patients who did not proceed to transplant, and what the addition of epcoritamab to R-DHAX/C could mean for patients with relapsed/refractory DLBCL.
Tolinapant Displays Encouraging Activity and Safety in Relapsed/Refractory PTCL/CTCL
Single-agent tolinapant generated promising response rates with a manageable safety profile in patients with relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma, according to data from the phase 2 ASTX660-01 trial.
FDA Grants Fast Track and Rare Pediatric Disease Designations to WU-CART-007 in R/R T-ALL and LBL
The FDA has granted fast track and rare pediatric disease designations to the CAR T-cell therapy WU-CART-007 for the treatment of patients with relapsed/refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.
Mosunetuzumab Monotherapy Generates Promising Responses in Relapsed/Refractory Follicular Lymphoma
July 20th 2022Single-agent mosunetuzumab produced a complete response rate that was greater than what has been observed with historical controls in patients with relapsed/refractory follicular lymphoma who had received at least 2 prior lines of therapy, meeting the primary end point of the expansion portion of the phase 1/2 GO29781 trial.
CB-010 Exhibits Impressive Early Efficacy in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
July 20th 2022The CAR T-cell therapy CB-010 displayed promising preliminary efficacy and safety results in patients with relapsed/refractory B-cell non-Hodgkin lymphoma according to findings from the phase 1 ANTLER trial presented during the 2022 Pan Pacific Lymphoma Meeting.
Polatuzumab Vedotin Plus R-CHP Significantly Extends PFS in Untreated DLBCL
July 19th 2022Polatuzumab vedotin, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone, induced a 27% reduction in relative risk for disease progression, relapse, or death for patients with newly diagnosed diffuse large B-cell lymphoma.
CHOP-Based Combinations Represent Evolving Standard of Care in Frontline Treatment of PTCL
Neha Mehta-Shah, MD, MSCI, discusses frontline therapies in peripheral T-cell lymphoma, highlighting the current treatment landscape and the need to explore more treatment options in clinical trials.
BTK Inhibitor–Based Combinations May Improve the Efficacy of SOC Treatment in CNS Lymphoma
July 19th 2022Avyakta Kallam, MBBS, discusses the benefits and shortcomings of the current standard of care in central nervous system lymphoma and expressed the importance of studying frontline targeted agents in this population.
Pirtobrutinib Demonstrates Encouraging Efficacy, Favorable Safety in Previously Treated CLL/SLL
Pirtobrutinib continued to produce promising responses in heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, irrespective of BTK C481 mutation status, reason for prior BTK inhibitor discontinuation, or other classes of previous therapy received.
Ibrutinib/Obinutuzumab Combo Elicits Durable Responses in Relapsed/Refractory CLL
Findings from a phase 1b trial showed that the addition of obinutuzumab to ibrutinib produced a complete response rate that compared favorably with what has historically been observed with ibrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia.